SCHEMBL21876566

SCHEMBL21876566

CCN(C)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Br)cc23)c1F

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.75
RIPK2 O43353 2/20 0.63
RAF1 P04049 2/20 0.63
KDR P35968 2/20 0.63
MAP2K2 P36507 2/20 0.63
TGFBR2 P37173 2/20 0.63
NEK2 P51955 2/20 0.63
MAP2K1 Q02750 2/20 0.63
TNK2 Q07912 2/20 0.63
MAP2K5 Q13163 2/20 0.63
PTK6 Q13882 2/20 0.63
NEK11 Q8NG66 2/20 0.63
MAP3K20 Q9NYL2 2/20 0.63
MAP4K5 Q9Y4K4 2/20 0.63
BMPR1B O00238 1/20 0.63
PLK4 O00444 1/20 0.63
PIR O00625 1/20 0.63
AURKA O14965 1/20 0.63
DCLK1 O15075 1/20 0.63
EPHB6 O15197 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30376067 0.94 BRAF (0.68) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL30313325 0.93 BRAF (0.66) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL25447210 0.93 BRAF (0.66) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL855539 0.93 BRAF (0.65) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL30313317 0.92 BRAF (0.70) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL25447209 0.92 BRAF (0.70) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL30376434 0.91 BRAF (0.68) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL24124793 0.91 BRAF (0.68) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL24320311 0.90 BRAF (0.62) BRAFRIPK2RAF1KDRMAP2K2
SCHEMBL15667553 0.90 BRAF (0.82) BRAFRIPK2RAF1KDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2024-05-21 US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 EP disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 US disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 US disclosed
WO-2021255212-A1 BRAF DEGRADERS F. HOFFMANN-LA ROCHE AG (CH) 2021-12-23 WO disclosed
WO-2021255212-A1 BRAF DEGRADERS F. HOFFMANN-LA ROCHE AG (CH) 2021-12-23 WO disclosed
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2021-11-16 US disclosed
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2021-11-16 US disclosed
EP-3846907-A1 POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES Arvinas Operations, Inc. (US) 2021-07-14 EP disclosed
US-20200129627-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES ARVINAS OPERATIONS, INC. 2020-04-30 US disclosed
US-20200129627-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES ARVINAS OPERATIONS, INC. 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129627-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL BRAF 4/4885RIPK2 974/4885RAF1 6/4885
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS BRAF 1/4885RIPK2 3359/4885RAF1 4/4885
US-11173211-B2 Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides CRBN, ARAF, VHL BRAF 4/4885RIPK2 974/4885RAF1 6/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 BRAF 1/4885RIPK2 1855/4885RAF1 3/4885
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL BRAF 4/4885RIPK2 974/4885RAF1 6/4885
US-11986531-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL BRAF 4/4885RIPK2 974/4885RAF1 6/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 BRAF 8/4885RIPK2 1749/4885RAF1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.